TY - JOUR
T1 - Age-specific incidence of breast cancer subtypes
T2 - Understanding the black-white crossover
AU - Clarke, Christina A.
AU - Keegan, Theresa H
AU - Yang, Juan
AU - Press, David J.
AU - Kurian, Allison W.
AU - Patel, Anish H.
AU - Lacey, James V.
PY - 2012/7/18
Y1 - 2012/7/18
N2 - Background Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). We used newly available populationbased data to examine whether the age-specific incidences of breast cancer subtypes vary by race and ethnicity. Methods We classified 91 908 invasive breast cancers diagnosed in California between January 1, 2006, and December 31, 2009, by subtype based on tumor expression of estrogen receptor (ER) and progesterone receptor (PR)-together referred to as hormone receptor (HR)-and human epidermal growth factor receptor 2 (HER2). Breast cancer subtypes were classified as ER or PR positive and HER2 negative (HR+/HER2-), ER or PR positive and HER2 positive (HR+/HER2+), ER and PR negative and HER2 positive (HR-/HER2+), and ER, PR, and HER2 negative (triple-negative). We calculated and compared age-specific incidence rates, incidence rate ratios, and 95% confidence intervals by subtype and race (black, white, Hispanic, and Asian). All P values are two-sided. Results We did not observe an age-related black-white crossover in incidence for any molecular subtype of breast cancer. Compared with white women, black women had statistically significantly higher rates of triple-negative breast cancer at all ages but statistically significantly lower rates of HR+/HER2- breast cancers after age 35 years (all P < .05). The age-specific incidence of HR+/HER2+ and HR-/HER2+ subtypes did not vary markedly between white and black women. Conclusions The black-white crossover in breast cancer incidence occurs only when all breast cancer subtypes are combined and relates largely to higher rates of triple-negative breast cancers and lower rates of HR+/HER2- breast cancers in black vs white women.
AB - Background Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). We used newly available populationbased data to examine whether the age-specific incidences of breast cancer subtypes vary by race and ethnicity. Methods We classified 91 908 invasive breast cancers diagnosed in California between January 1, 2006, and December 31, 2009, by subtype based on tumor expression of estrogen receptor (ER) and progesterone receptor (PR)-together referred to as hormone receptor (HR)-and human epidermal growth factor receptor 2 (HER2). Breast cancer subtypes were classified as ER or PR positive and HER2 negative (HR+/HER2-), ER or PR positive and HER2 positive (HR+/HER2+), ER and PR negative and HER2 positive (HR-/HER2+), and ER, PR, and HER2 negative (triple-negative). We calculated and compared age-specific incidence rates, incidence rate ratios, and 95% confidence intervals by subtype and race (black, white, Hispanic, and Asian). All P values are two-sided. Results We did not observe an age-related black-white crossover in incidence for any molecular subtype of breast cancer. Compared with white women, black women had statistically significantly higher rates of triple-negative breast cancer at all ages but statistically significantly lower rates of HR+/HER2- breast cancers after age 35 years (all P < .05). The age-specific incidence of HR+/HER2+ and HR-/HER2+ subtypes did not vary markedly between white and black women. Conclusions The black-white crossover in breast cancer incidence occurs only when all breast cancer subtypes are combined and relates largely to higher rates of triple-negative breast cancers and lower rates of HR+/HER2- breast cancers in black vs white women.
UR - http://www.scopus.com/inward/record.url?scp=84864421010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864421010&partnerID=8YFLogxK
U2 - 10.1093/jnci/djs264
DO - 10.1093/jnci/djs264
M3 - Article
C2 - 22773826
AN - SCOPUS:84864421010
VL - 104
SP - 1094
EP - 1101
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 14
ER -